Thermo Fisher Scientific, Genetron Health Partner on NGS-Based Cancer Dx in China

Jun 11, 2020

|

NEW YORK – Genetron Health announced Thursday a strategic partnership with Thermo Fisher Scientific to commercialize next-generation sequencing-based diagnostics in China.

The deal will bring the Genetron S5, which is based on Thermo Fisher's Ion GeneStudio S5 instrument for targeted NGS, to China's public hospitals for use in cancer diagnostics, genetic disease diagnosis, microbial testing, and reproductive health testing, among other uses.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep

10

Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Menu

Thermo Fisher Scientific, Genetron Health Partner on NGS-Based Cancer Dx in China

To read the full story....

Breaking News

Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

Genentech's Tecentriq, Paclitaxel Combo Fails to Improve PFS in PD-L1-Positive TNBC

Canbridge Pharmaceuticals Receives Marketing Approval in Taiwan for Puma's Nerlynx

Aethlon, UPMC Land $3.5M NIDCR Grant to Explore Exosome Depleting Capability of Hemopurifier

Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk

Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Featured White Papers

Utility of Novel RNA-Based Tools in Oncology Drug Development

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

What's Popular?

Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk

Real-World, Umbrella Studies Highlight Challenges of Evaluating Precision Oncology in NSCLC

Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Sponsorships